AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

Navigating the Future of Cancer Diagnostics and Liquid BiopsyThe global healthcare landscape is witnessing a massive shift toward precision medicine. At the heart of this revolution lies the study of ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and ...

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a ...

Good morning, everyone, and welcome to the Abeona Therapeutics Full Year 2025 Results Conference Call. [Operator Instructions] Please note this conference is being recor ...

Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous cell-based gene therapy approved in April 2025 for adults and pediatric ...

First ZEVASKYN- commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 - - $191.4M in cash, cash equivalents and short-term investments as of ...

Anti-inflammatory therapies that are highly effective for inflammatory skin diseases might also be relevant to depression ...

Integrative high-throughput studies identify novel targets and drugs for advanced prostate cancer treatment Prostate cancer, a prevalent malignancy ...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026U.S. Food and Drug ...